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Abstract
Mutations in valosin-containing protein (VCP), an ATPase involved in protein degradation and 
autophagy, cause VCP disease, a progressive autosomal dominant adult onset multisystem 
proteinopathy. The goal of this study is to examine if phenotypic differences in this disorder could 
be explained by the specific gene mutations. We therefore studied 231 individuals (118 males, 113 
females) from 36 families carrying 15 different VCP mutations. We analyzed correlation between 
the different mutations and prevalence, age of onset and severity of myopathy, PDB, and FTD, and 
other comorbidities. Myopathy, PDB and FTD was present in 90%, 42% and 30% of the patients 
respectively, beginning at an average age of 43 years, 41 years, and 56 years respectively. 
Approximately 9% of patients with VCP mutations had an ALS phenotype, 4% had been 
diagnosed with Parkinson’s disease (PD), and 2% had been diagnosed with Alzheimer’s disease 
(AD). Large inter and intra-familial variation made establishing correlations difficult. We did not 
find a correlation between the mutation type and the incidence of any of the clinical features 
associated with VCP disease, except for the absence of PDB with the R159C mutation in our 
cohort and R159C having a later age of onset of myopathy compared to other molecular subtypes.
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• Mutations in valosin-containing protein (VCP) cause inclusion body myopathy, Paget 
disease of bone, frontotemporal dementia, amyotropic lateral sclerosis and Parkinson’s 
disease.
• We studied the largest group of individuals (total 231: 118 males, 113 females) from 
36 families carrying 15 different VCP mutations to establish genotype-phenotype 
correlation.
• Large intra-familial and interfamilial variations made establishing correlations difficult 
to establish except for later age of onset with R159C mutations.
Introduction
Inclusion body myopathy associated with Paget’s disease of bone and frontotemporal 
dementia (IBMPFD) or multisystem proteinopathy is an adult-onset progressive, autosomal 
dominant ultimately lethal disease that involves degeneration of three main organ systems: 
muscle, bone, and brain. Most cases are caused by heterozygous missense mutations in 
valosin-containing protein (VCP) (1), (2). As awareness increases we are realizing that VCP 
disease is not as rare as previously considered since it is often misdiagnosed as related 
disorders.
Pathology of IBMPFD
Inclusion body myopathy (IBM) is characterized by progressive weakness and atrophy of 
skeletal muscles of pelvic and shoulder girdle muscles. Ultimately, patients die from 
respiratory failure, cardiomyopathy and cardiac failure (3). Histologically, IBM consists of 
cytoplasmic rimmed vacuoles containing the same proteins that aggregate in the brains of 
patients with neurodegenerative diseases: tau, amyloid, and TDP-43 (TAR DNA binding 
protein 43) (4).
Paget’s disease of bone (PDB) is a unique skeletal disease caused by an imbalance between 
osteoclast and osteoblast function. The result is a gain in bone mass, but the new bone is 
disorganized, weak, and prone to fractures. Typical radiological findings of PDB including 
coarse trabeculation, cortical thickening and spotty sclerosis. Clinical features include bone 
pain, bone enlargement, fractures, hearing loss due to auditory foramen narrowing, and 
arthritis. Rare complications include kidney stones, osteosarcoma, and high-output heart 
failure due to the formation of arteriovenous shunts in bone (5).
Frontotemporal dementia (FTD) is an early-onset type of dementia that is typically 
diagnosed in younger patients roughly 60% occurring in people 45–64 years old (6), 
however in VCP disease is associated with an earlier age of onset. Degeneration and atrophy 
of the frontal and temporal lobes of the brain results in changes in personality and 
progressive loss of language. Brain histology in patients with IBMPFD affected by FTD is 
characterized by gliosis, spongiosis, and neuronal intranuclear inclusions (7). TDP-43 
aggregates are commonly associated with VCP-associated FTD as well as in amyotrophic 
lateral sclerosis (ALS) (4, 8, 9). TDP-43 is a DNA/RNA-binding protein involved in various 
cellular processes including RNA transcription and splicing (10–12). We have previously 
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shown that the presence of one or two APOE4 alleles is associated with an increased risk of 
developing FTD in patients with VCP disease (13).
Mutations in VCP have also been associated with a spectrum of other diseases including 
amyotrophic lateral sclerosis (ALS) (14), hereditary spastic paraplegia (15), Charcot-Marie-
Tooth Type 2 disease (16). Other common disorders that have an overlap with VCP disease 
include facioscapulohumeral muscular dystrophy (FSH), Limb-girdle muscular dystrophy 
(LGMD), scapuloperoneal muscular dystrophy (SPMD), inclusion body myositis, and distal 
myopathy/oculopharyngeal muscular dystrophy (17).
Structure and Function of VCP
VCP has four domains: an N-terminal ubiquitin binding domain, two ATPase domains (D1 
and D2), and a C-terminal region (18). Valosin is a 25 amino acid peptide named after its N-
terminal valine and C-terminal tyrosine, and was originally isolated from the porcine gut 
(19). That peptide sequence is present in valosin-containing protein, which is a highly 
abundant ATPase found in all cells where it interacts with various adaptor proteins to carry 
out many essential cellular processes. Among them are endoplasmic reticulum-associated 
degradation (20), transcription factor processing (21), nuclear envelope reconstruction (22), 
membrane fusion (23), post mitotic golgi reassembly (24), spindle disassembly (25), and cell 
cycle control (26). Several of these activities are associated with the ubiquitin-proteasome 
system in which VCP helps deliver ubiquitylated substrates to the 26S proteasome for 
degradation (27). VCP’s roles in protein degradation and autophagy is implicated in the 
pathogenesis of IBMPFD, and may account for the cytoplasmic inclusions observed in 
muscle, bone, and neuronal tissue (1, 27). The hypothesis is that the location of the mutation 
may influence certain roles of VCP and thus lead to variation in the phenotype seen in VCP.
The goal of this work was to determine the location and type of the 15 different mutations in 
the VCP gene in 231 individuals from 36 families recruited initially for our gene 
identification studies and later for genotype-phenotype analyses.
Methods
Clinical Evaluation and Diagnosis
Informed consent was obtained from each subject prior to participation. Research studies 
were approved by the Institutional Review Boards of Southern Illinois School of Medicine, 
Springfield, IL. Children’s Hospital, Boston, MA, and University of California, Irvine, CA. 
Individuals who participated in clinical, biochemical, and molecular studies were over age 
18 years. This is essentially a cross sectional study, however follow-up of most patients 
occurred at periodic intervals and documentation. Subjects were grouped into three 
categories based upon their mutation status; symptomatic, asymptomatic carriers and non-
carrier first degree at risk relatives. Affected individuals were grouped into fifteen groups 
based on their VCP mutation R155H, R155C, R155P, R191Q, R159C, R159H, L198W, 
R95G, R93C, A232E, N387H, G97E, A160P, G128A, and M158I.
A diagnosis of myopathy was based on the presence of muscular weakness, elevated total 
creatinine kinase (CK) in some individuals, and in several patients by EMG and muscle 
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biopsy findings. Clinical findings suggestive of myopathy included an inability to raise their 
arms and walk upstairs, a lordotic gait from the proximal weakness and in some mild 
weakness of the hands. Tendon reflexes were absent or reduced. Electrodiagnostic studies 
including electromyography and nerve conduction studies were performed as standard of 
care procedures to look for myopathic/neuropathic changes. Muscle biopsies were obtained 
from the majority of individuals for clinical diagnoses which often led to the clinical 
diagnosis of inclusion body myopathy. The results of the muscle histology in several patients 
was reviewed previously and summarized for this report.
Diagnosis of PDB include clinical features like spine or hip pain, pathologic fractures and 
long bone or cranial bone deformity. Measurements of serum alkaline phosphatase (ALP), a 
marker of bone turnover, and urine pyridinoline and deoxypyridinoline were made in all 
individuals. Skeletal X-Rays were obtained in most patients with VCP mutations because of 
the known high incidence of PDB. Skeletal radiologic surveys included views of the skull, 
spine, hips, long bones, hands, and feet. Radionucleotide scans show focally increased bony 
uptake and are considered more sensitive indicators of PDB than plain survey films. 
Radionuclide scans were obtained in individuals previously diagnosed with PDB. A 
selection of patients and gene carriers at risk of PDB participated in the detailed 
phenotyping studies at UC Irvine had radionuclide scans followed by X-rays of regions that 
were suspicious for PDB.
The diagnosis of frontotemporal dementia is typically made by a comprehensive 
neuropsychological assessments and imaging studies together with assessment of behavioral 
and personality changes, like personal/social unawareness, perseveration, and disinhibition. 
A selection of patients were tested with a standard battery targeted to assess FTD including 
MMSE, Trails A & B, short version of the Stroop test, digit span, letter and category fluency 
and Boston naming, plus the neuropsychiatric in (NPI- short version) and Beck Depression 
Inventory for behavioral symptoms. In some patients with advanced dementia 
comprehensive neuropsychological testing was not possible and the diagnosis was made 
based on the strong family history of FTD. Patients were diagnosed with ALS according to 
the El Escorial criteria which are highly specific for ALS (28).
Molecular Studies
Mutation analysis of the VCP gene (NM_007126) was carried out as previously described in 
CLIA certified DNA diagnostic laboratories at the Mitomed Laboratory at UC Irvine, CA or 
at Prevention Diagnostic Laboratory, Marshfield, WI.
Statistical analysis
One-way ANOVA and Bonferroni Post Hoc analysis were performed using SPSS® 
statistical package (v. 21). Only mutation groups with more than 5 patients were included in 
the one-way ANOVA. Population standard deviations are reported since this is a rare disease 
and this study represents the largest assembly of patients published to date.
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Results
Clinical data from 231 individuals representing 36 families carrying fifteen different VCP 
mutations (118 males, 113 females) was analyzed. Of these individuals, 187 (98 males, 89 
females) were clinically symptomatic, and 44 (20 males, 24 females) were presymptomatic 
carriers. Our cohort of patients include mixed European, Brazilian, Hispanic/Apache, and 
African-American male.
Myopathy
Of the 187 symptomatic individuals with VCP mutations, 168 (89.84%) presented with 
myopathy at a mean age of onset of 43 years (range 20 – 70 years) (Table 1). Among all 
symptomatic VCP patients, mean CK levels were 182.9 ± 16.94 U/L (SD 160.67) with a 
range of 34–473 mg/dl. Among VCP patients who were diagnosed with myopathy, CK was 
187.4 U/L (SD = 161.75, SEM 17.03, Range 32–909). Among presymptomatic gene 
carriers, CK was 169.91 ± 25.34 U/L (SD 145.56, SEM 25.7, Range 54–736 U/L), 
compared to 117.94 ± 9.00 U/L (SD 80.46, SEM 9.0) in our unaffected normal subjects 
(p<0.006) suggesting that CK elevations may be early indicators of muscle pathology. A 
weak negative correlation coefficient of −0.2 was found between CK levels and age of onset 
of myopathy.
EMG results were obtained in 138 myopathic individuals as routine clinical evaluations in 
the majority of individuals and as part of research studies at the University of Kentucky and 
UC Irvine. Forty-five (32.6%) of individuals had pure myopathic changes, 16/138 (11.6%) 
had neurogenic changes, and 19/138 (13.8%) showed both myopathic and neurogenic 
changes on EMG.
Muscle biopsy reports were available for 115 of the symptomatic individuals. Muscle 
biopsies were obtained as standard of care in most patients and the reports and available 
histology slides reviewed. Histopathology showed that only 46 of the 115 (40%) muscle 
biopsies studied had rimmed vacuoles and the remaining individuals had non-specific 
myopathic changes. We have previously published our muscle biopsy findings in different 
cohorts of patient groups (2) (4) (29) (30).
Paget’s disease of bone (PDB)
PDB was identified in 79 individuals (42.4% of those with VCP mutations) with a mean age 
of onset of 41.2 years (range 23 – 65 years). Mean alkaline phosphatase (ALP) among all 
symptomatic individuals as 289.8 ± 44.9 IU/L (SD = 434.85, SEM 45.09, median 127.0, 
Range 9–3006). Among individuals diagnosed with PDB, the mean ALP was 414.1 IU/L 
(SD = 544.08, SEM 75.45, Range 16 – 3006), (p<0.001). The ALP levels among 
presymptomatic gene carriers and non-carriers were similar (87.7 ± 5.4, SD = 31.6, SEM 
5.5, Range 17–164, median 79.0, and 91.1 ± 5.1, SD = 46.84, SEM 5.17, Range 32–269, 
Median 79.5 respectively) (normal ALP is 44 to 147 IU/L). Most individuals had 
radionuclide scans and/or radiographs. Bones with a predilection for PDB included the skull, 
pelvis, and spine and interestingly the long bones were generally spared from PDB. We 
found that radionuclide scans obtained in presymptomatic individuals identified Paget 
Al-Obeidi et al. Page 5
Clin Genet. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
lesions in several bones which would not have been diagnosed by elevations in ALP levels 
alone.
Neurodegenerative diseases
Dementia was diagnosed in 55 (29.4%) symptomatic individuals with VCP mutations and 
occurred at a mean age of 55.9 years (range 30 – 86 years). Since this is a cross-sectional 
study and FTD occurred later in the course of the disease typically being associated with 
rapid progression of the disease, we gathered data on the neuropsychological studies by their 
local clinicians. Detailed clinical studies were not always possible in severely demented 
individuals; also many individuals are not old enough to develop FTD, thus a comprehensive 
analysis of the various subtypes of FTD among these subjects is beyond the scope of this 
study. Clinical features (17, 31–33) tends to be typical including sociobehavioral and 
language changes, usually an expressive dysphasia, and loss of executive function. 
Characteristic findings include ubiquitin and TDP-43-positive neuronal intranuclear 
inclusions and dystrophic neurites.
Across all 36 families, there were 16 individuals (8.6%) representing six different genotypes 
(Table 1) who were diagnosed with an ALS phenotype of upper and lower motor neuron 
degeneration. Because of the rapid progression of ALS in these patients we reviewed clinical 
records and found unequivocal evidence of upper motor neuron dysfunction in three subjects 
from family 2, 3 and 57, the remaining subjects manifesting combined upper and lower 
motor neuron features. Asymmetry was marked in some individuals such as noted in the 
proband in family 57 who had clonus of the left leg and myopathic features of the right leg.
Autopsy data available on one individual with ALS revealed loss of brainstem and spinal 
cord motor neurons with Bunina bodies in surviving anterior horn cells and TDP-43 
immunostaining, consistent with the diagnosis of ALS.
Seven individuals (3.8%) had been diagnosed with Parkinson’s disease (PD). Two had 
R155H mutations (family 52 and 56), two had R159C mutations (family 24), two had 
A160P mutations (family 59), and one had G128A (family 61) (table 2). Patients with PD in 
VCP disease tend to have classical symptoms and respond well to standard treatment. 
Detailed evaluations were performed in two individuals in family 24; studies of the proband 
are provided in the clinical report by Chan et al. (2012) indicated that he had classic PD and 
responded well to therapy (34).
Four individuals (2.1%) were diagnosed with Alzheimer’s disease: one had the G97E 
mutation (family 50), one had the R159H mutation (family 55), and one had R155H (family 
3). We previously reported a case of early onset Alzheimer with two APOE4 alleles in 
family 2 (13).
Although VCP multisystem disorder is associated with a triad of symptoms, only 10% of the 
patients in our study presented with all three main features of the disorder (Figure 1). 
Myopathy was the most common presenting symptom, presenting in 89% of patients and as 
an isolated symptom in 36%. PDB was diagnosed in 43% of patients, and in 5% it was the 
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sole clinical feature. Twenty-nine percent of patients had FTD, and in 3% this was the sole 
feature.
Genotype-phenotype studies
To elucidate the effect of different mutations on phenotypic variations, the families were 
divided into 15 groups according to their VCP mutation (Table 1, 2). Most mutations 
involved exon 5 which was mutated in 83% of individuals followed by mutations in exon 6 
in 8% individuals. The frequency and mean age of onset of myopathy, PDB, and FTD, ALS, 
PD and AD as well as biological markers (CK, ALP) for each mutation group were 
compared to identify any statistically significant differences. Some of the mutation groups 
were too small for a statistical analysis of this sort. For IBM, mutation group R159C was 
found to have a later age on onset of muscle weakness (57 years) compared to L198W (37 
years), R155H (43 years), R155P (43 years) and R155C (38 years), (p=<.04). No 
statistically significant differences were identified for PDB or FTD. We also did not see a 
higher incidence of ALS, or Parkinson’s disease either with any specific mutation types. The 
G97E mutation was reported to be associated with Charcot-Marie-Tooth (CMT2) (35); 
however, we did not find any case of CMT in our cohort of patients.
Discussion
VCP disease is an autosomal dominant syndrome associated with progressive inclusion body 
limb-girdle type myopathy, Paget’s disease of bone, frontotemporal dementia (IBMPFD), 
and ALS. We report genotype-phenotype studies in patients bearing one of the 15 mutations 
in this report amongst our cohort to determine whether correlations exist between a patient’s 
mutation and the age of onset of their symptoms and associated manifestations. The primary 
findings are the general lack of genotype-phenotype correlations because of the enormous 
phenotypic heterogeneity within and between families. We found an incidence of 90% for 
the myopathy, 42% for PBD, 30% for FTD, 9% for ALS, and 4% for Parkinson’s disease 
(Table 1). Detailed analysis of VCP patients however shows motor neuron involvement is 
apparent in the majority of study participants. Benatar et al. (2013) found three patients with 
unequivocal UMN findings and four with subtle UMN findings in a cohort of ten patients 
from six VCP families (36).
Although the levels were in the normal range there was large variability in the value of CK 
we noted that the levels were higher among presymptomatic gene carriers, compared to their 
unaffected relatives suggesting that mild CK elevations may be early indicators of muscle 
pathology in some individuals. Similarly, we noted that ALP was overall much higher in the 
presymptomatic carriers without PDB than their non-carrier relatives indicating it may be a 
good marker for early diagnosis of PDB. Radionuclide bone scans are also sensitive in 
establishing the early diagnosis of PDB having identified several presymptomatic 
individuals with normal ALP levels. Radionuclide bone scans thus offers the potential to 
treat patients presymptomatically in order to prevent PDB from progressing. Our data has 
also shown that VCP-associated PDB has a mean earlier onset of 41.2 years compared to 
PDB in the general population with an average age of onset of 50 years (2). Similarly, VCP 
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associated FTD is associated with an early onset form of dementia at an average age of 55.9 
years versus a typical age of onset of 65 years (6).
Genotype-phenotype correlation
There are 17 exons in the VCP gene and mutations have been reported in 11 of them - the 
vast majority occurring in exon 5. The only exons not identified with a mutation are exons 1, 
8, 9, 13 and 15 (Table 4) suggesting that mutations in these loci are yet to be identified, or 
potentially devastating compromising survival of the individual. A total of 42 mutations have 
been previously published, in addition to the 3 novel missense mutations reported herein. 
Most the mutations are in the N terminus of VCP which is responsible for binding cofactors 
and ubiquitylated protein substrates (37–39). The mutations associated with IBMPFD and/or 
familial ALS are all exonic missense mutations. In particular, the R155 locus is a mutation 
hotspot. Previous genotype-phenotype analysis showed that the R155C mutation was 
associated with an earlier age of onset of myopathy and PDB (2) however analysis of a 
larger dataset in this report did not confirm this finding. The only statistically significant 
difference between the mutation groups was the later age of onset of myopathy in patients 
with the R159C mutation compared to the R155H, R155C, R155P, and L198W mutations. 
This suggests that there may not be significant differences in the age of onset of symptoms 
among IBMPFD patients with different VCP mutations; however, some of the groups are too 
small for this type of analysis. We previously reported that the A232E mutation is associated 
with a more severe phenotype (1) in a small family. This report is supported by our data 
which shows the A232 mutation as having an earlier onset of PDB compared to average and 
an ALS phenotype (Table 1). Functional studies by Niwa et al. (2012) who tested ten VCP 
mutations (R93C, R95G, R155C, R155H, R155P, R159H, R191Q, L198W, A232E, and 
N387H) and found that all have increased ATPase activity over the wild type, with the 
A232E mutant having three times higher activity (18, 40). Interestingly the R159C mutation 
was associated with a later age of onset of myopathy compared to other molecular subtypes 
in our cohort of families. Additionally, PDB was absent in this large family, and also in two 
other reported families (11, 41). PDB was seen only in one individual with this mutation in 
an ALS family (42) suggesting a protective effect of the R159C mutation from PDB.
Global distribution and ethnic diversity of VCP mutations
Our cohort of patients recruited in North America included individuals of mixed European 
descent, Brazilian families, an African-American family and a family of Hispanic/Apache 
descent (17, 29, 30), Among families of European ancestry, patients of German (17, 43), 
Italian (41, 44, 45), Spanish (46), Austrian (47), Belgian (48), French (49), Irish (50), and 
British (51–53) backgrounds have been identified. In Asia, Korean (54), Japanese (55), and 
Chinese (56), families have been reported. Gonzalez-Perez (42) described an Israeli-Arab 
family. Brazilian (31) and Australian (57) cases have also been described. The Miller et al 
study (58) is the only that proposes an incidence of 1/300,000 among Scottish patients and 
1/600,000 for British patients with VCP disease. The incidence in the US is most likely 
similar since patients do not always have the typical features of the syndrome and are 
diagnosed with related disorders such as limb-girdle muscular dystrophy, inclusion body 
myositis, and FSH especially in the absence of a family history of the other manifestations.
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Figure 1. 
Frequencies of phenotypes in 187 individuals
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